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Abstract
Background: HM-3 is a polypeptide inhibiting angiogenesis. Recent reports suggest that the antitumor effect of
angiogenesis inhibitors administered alone might be limited. Cancer stem cells can survive the lack of oxygen and
nutrients. To achieve better anti-tumor effect, HM-3 was administered in combination with the attenuated
Salmonella typhimurium VNP20009 transformed with a shRNA construct against sex determining region Y-box 2
(Sox2).
Methods: Cell invasion assay and soft agar colony formation assay were used to assess the migration and growth
capability of A549 cells once Sox2 was knocked down with the shRNA construct. The shRNA construct targeting
Sox2 was transformed into VNP20009. After the mouse xenograft model of A549 was established, HM-3 was
co-administered with VNP20009 carrying the shRNA construct. The growth of tumor was checked to compare the
effectiveness of different therapies. Western blotting assay and immunohistochemistry staining of the tumor tissue
were used to measure the levels of proteins associated with the apoptosis pathway.
Results: Sox2 was necessary for the migration and growth of A549 cells. The expression of Sox2 was down
regulated in the tumor tissue of the combined treatment group of HM-3 with VNP20009 carrying the Sox2 shRNA
construct. Together with the accumulation of salmonella in tumor and the inhibition of angiogenesis by HM-3,
more tumor cells went through cell apoptosis with increased expression of Bax, cleaved Caspase 3 and decreased
expression of Bcl2.
Conclusions: The results suggest the combination of antiangiogenesis agent HM-3 with gene therapy targeting
Sox2 delivered by salmonella as a promising strategy for the treatment of lung cancer.
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Background
Lung cancer is one of the leading causes of cancer-
related death throughout the world. The average 5-year
survival rate of non-small cell lung carcinoma (NSCLC)
which accounts for 85 % of lung cancers is only 4 %,
highlighting the need for more effective treatment
options [1]. HM-3 is an 18-amino acid peptide generated
by the fusion of the Arg-Gly-Asp (RGD) sequence to the
C-terminus of an endostatin-derived peptide. Our previ-
ous research has shown that HM-3 has no effect on the
growth of tumor cells in vitro. However, HM-3 can
inhibit tumor growth by inhibiting angiogenesis in vivo
[2, 3]. The binding of HM-3 to integrin αvβ3 expressed
on the surface of vascular endothelium cells (VECs) re-
sults in the down-regulation of MEK1 and AKT1, lead-
ing to the inhibition of the migration of VECs [4–6].
HM-3 has been approved for phase I clinical study in
China (Register number: CTR20150368). Recent studies
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reported that the antitumor effect of angiogenesis inhibi-
tors (AIs) administered alone might be limited implicating
that additional tumor targeting drugs should be co-
administered with AIs [7–9].
Tumor growth is sustained by a small number of
tumor-initiating cells known as cancer stem cells (CSCs).
Sox2, a gene expressed at high level in stem cells, also
plays a vital role in the regenesis of lung CSCs [10–12]. It
has been reported that the growth and metastasis of cer-
tain cancer cells were suppressed when Sox2 was down
regulated suggesting Sox2 may be a potential target for
cancer treatment [13, 14]. Finding an effective way to de-
liver Sox2 shRNA constructs into lung cancer cells may
achieve better anti-tumor effect. Among the gene therapy
delivery systems reported, attenuated salmonella offers
more advantages as it can preferentially accumulate and
amplify in solid tumor with little toxicity to normal or-
gans. Also, it has been used as gene therapy delivering sys-
tem for many shRNA constructs targeting different genes
such as indoleamine 2, 3-dioxygenase 1 (IDO1) [15], mul-
tiple drug resistance 1 (MDR1) [16] and murine double
minute 2 (MDM2) [17].
Here, we explored the antitumor effect of the novel com-
bination therapy of HM-3 with VNP20009 carrying a Sox2
shRNA construct in a mouse xenograft model of NSCLC.
Our results showed that the combined therapy had the op-
timal antitumor effect compared to HM-3 alone or doce-
taxel alone. The optimal therapeutic effect was achieved
through accumulation of VNP20009 in tumor tissue, sup-
pression of the expression of Sox2 and inhibition of angio-
genesis in tumors. More tumor cells went through cell
apoptosis in the combined treatment group. Also, no ap-
parent toxic side-effect was observed in the mice.
Methods
Cell lines, animals and drugs
The NSCLC cell line A549 was purchased from Shanghai
Institute of Cell Biology, Chinese Academy of Sciences
(Shanghai, China). A549 cells were maintained in RPMI-
1640 medium containing 10 % FBS. Athymic BALB/c
nude female mice (5 weeks) were purchased from
CAVENS (Changzhou, China). HM-3 (sequence: IVRRA-
DRAAVPGGGGRGD) with purity of more than 99 % was
chemically synthesized in our lab. The antibodies against
Sox2 and CD31 were purchased from Santa Cruz (Dallas,
USA). The antibodies against Bax and Bcl2 were obtained
from Wanleibio (Dalian, China). The antibody against
cleaved Caspase 3 was obtained from Elabscience
(Wuhan, China). Docetaxel Injection was purchased from
Hengrui (Jiangsu, China).
Plasmids and bacterial strains
The mammalian shRNA expression plasmid (pGPU6/
Neo) targeting Sox2 was constructed by GenePharma
(Shanghai, China). The shRNA sense sequence targeting
Sox2 was TGGACAGTTACGCGCACATGA as reported
and the scrambled shRNA sense sequence was
GTTCTCCGAACGTGTCACGT [18]. The scrambled
shRNA construct was referred as shScr while the Sox2
shRNA construct was referred as shSox2. The shRNA
construct was electroporated into VNP20009 with a
Gene Pulser Xcell system (Bio-Rad) at 2.5 kV, 186 ohms
[15]. VNP20009 transformed with the shScr (shScr-V)
and VNP20009 transformed with the shSox2 (shSox2-V)
was cultured in Luria-Bertani (LB) broth supplemented
with ampicillin (50 μg/ml) [19]. The shRNA constructs
were isolated and the targeting sequence was confirmed
by sequencing. To calculate the number of colony form-
ing unit (cfu) in culture, an optical density of 1.0 mea-
sured at 600 nm equal to 109 cfu/ml was used.
Cell invasion assay and soft agar colony formation assay
The cell invasion assay was performed using 24-transwell
chambers (Corning, Newyork, USA). The procedures were
carried out as previously reported [12]. For soft agar col-
ony formation assay, a layer of media with 0.5 % agarose
was first plated onto the bottom of a 6-well plate. 1 × 104
cells/well were plated in a top layer of media with 0.33 %
agarose. After stained with 0.005 % crystal violet, images
were taken under an inverted microscope (Olympus IX53)
after three weeks. The number of colonies was counted
from multiple random fields.
Tumor models and treatment
2 × 106 A549 cells were injected subcutaneously (s.c) on
the right flanks of the nude mice. The width (W) and
length (L) of each tumor was measured with a vernier
caliper. Tumor volume (TV) was determined with the
formula: TV = L × W2/2. When the mean tumor vol-
umes reached 300 mm3, the mice were randomly
assigned into seven groups (n = 6 at least): (1) the mice
received 200 μl normal saline (NS) intravenously as the
normal control; (2) 2.5 × 106 cfu of shScr-V diluted in
NS was administered intravenously on day 1; (3) 2.5 ×
106 cfu of shSox2-V diluted in NS was administered
intravenously on day 1; (4) HM-3 diluted in NS was ad-
ministered intravenously at a dose of 3 mg/kg/day; (5)
both HM-3 and shScr-V was administered as for their
individual treatment regimens; (6) both HM-3 and
shSox2-V was administered as for their individual treat-
ment regimens; (7) docetaxel was administered intraven-
ously at a dose of 10 mg/kg every four days for three
injections. All the groups were listed in Table 1. Inhib-
ition rate = [(tumor weight of control group – tumor
weight of experimental group)/tumor weight of control
group] × 100 %.
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Assay of VNP20009 in tissues and blood
After the A549 tumor model in nude mice was estab-
lished, VNP20009 was administered by intravenous in-
jection at a dose of 2.5 × 106 cfu per mouse. On days
2, 7 and 14 after injection, tumors and major organs
were aseptically removed, weighted and homogenized
in PBS. 1 ml homogenized tissue of the same weight
(100 mg) was diluted in gradient and 100 μl was
plated onto LB agar plates containing ampicillin (50
μg/ml). In the case of blood analysis from mice, 200
μl blood was collected as the mice were killed and
was plated directly onto the LB plates. The LB plates
were incubated at 37 Celsius overnight and the bac-
teria colonies were quantified.
Western blotting assay (WB)
The tumor samples were snapped into small pieces
and incubated with RIPA cell lysis buffer supple-
mented with protease inhibitors on ice for 20 min.
After that, the samples were homogenized with a
glass tissue grinder. After centrifuging (14,000 × g)
for 20 min, the supernatant was removed and boiled
with protein loading buffer. The western blotting was
carried out as described before [5]. ImageJ software
(Wayne Rasband, USA) was used to analyze the re-
sult. The relative protein expression was calculated by
dividing the optical density of the protein analysed
with the optical density of β-actin of the same group.
The results of three independent experiments were
calculated.
Immunohistochemistry (IHC)
Tumor and organ tissue was fixed in 4 % formalin and
embedded in paraffin. Sections were deparaffinized and
rehydrated. For hematoxylin and eosin (H&E) staining,
sections were stained in hematoxylin and then counter-
stained with eosin. For immunohistochemistry staining,
after treatment with 3 % H2O2, sections were boiled in
10 mM sodium citrate buffer (pH 6.0) for antigen re-
trieval. After blocking, sections were incubated with the
primary antibody as recommended by the supplier,
washed with PBS, and then incubated with the horserad-
ish peroxidase labeled secondary antibody. Sections were
finally incubated with DAB and counterstained with
hematoxylin.
Statistical analysis
All the data was collected and processed with the Statis-
tical Program for Social Sciences (SPSS version 13.0,
Chicago, USA). The difference between samples of the
same group was tested by one-way analysis of variance. It
would be considered statistically significant when P < 0.05
and statistically highly significant when P < 0.01.
Results
The invasion and anchorage-independent growth capability
of A549 cells was inhibited as Sox2 was knocked down
To confirm the effectiveness of the shRNA constructs,
the expression of Sox2 at protein level in A549 cells was
analysed with WB after transfected with the shRNA con-
structs. Compared to the A549 cells transfected with
shScr, the expression of Sox2 was reduced by more than
80 % in the cells transfected with shSox2 (Fig. 1a, P <
0.01). The number of cells that migrated was 236.33 ±
26.08 for A549 cells transfected with shScr, while it was
45.23 ± 12.50 for A549 cells transfected with shSox2
(Fig. 1b, P < 0.01). The number of colonies that formed
was 225.33 ± 62.98 for A549 cells transfected with shScr,
while it was 57.33 ± 12.01 for cells transfected with
shSox2 (Fig. 1c, P < 0.05). Sox2 plays an important role
in regulating the migration and anchorage-independent
growth of A549 cells. Therefore, Sox2 may be consid-
ered as a potential target for the treatment of lung
cancer.
VNP20009 selectively accumulated in tumors
To ensure that VNP20009 transformed with the
shRNA expression plasmid still preferentially accumu-
lated in solid tumor tissues, the distribution of shScr-
V in the A549 xenografts and major organs of mice
treated with shScr-V was monitored. On days 2 post-
injection, the amount of shScr-V in tumors was
significantly higher than it was in spleen and other
organs (Fig. 2a). No shScr-V was detected in the
blood on days 2 suggesting that the environment in
blood was not well adapted by VNP20009 [20]. Quan-
titative analyses showed that on days 2, 7 and 14 after
injection, shScr-V could maintain its accumulation in
tumors over spleen and other organs at a ratio
greater than 1000:1 (Fig. 2b, P < 0.01).
Antitumor activity of HM-3 combined with shSox2-V
in vivo
After the mouse xenograft model of A549 was estab-
lished, the mice were assigned randomly to seven groups
Table 1 Treatment groups
Group Treatment
Mock Normal saline (NS) was administered as control
shScr-V VNP20009 carrying the scrambled shRNA construct
was administered
shSox2-V VNP20009 carrying the Sox2 shRNA construct
was administered
HM-3 HM-3 was administered
HM-3 + shScr-V Both HM-3 and shScr-V were administered
HM-3 + shSox2-V Both HM-3 and shSox2-V were administered
Docetaxel Docetaxel was administered
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(Fig. 3a and Table 1). HM-3 was administered alone and
in combination with shScr-V or shSox2-V. Although the
tumor growth of the shSox2-V, HM-3 + shScr-V and do-
cetaxel groups all had been suppressed compared to the
mock group (P < 0.05, respectively), the best therapeutic
effect was obtained in the HM-3 + shSox2-V group
(Fig. 3b, P < 0.01). The mean tumor volume of the HM-
3 + shSox2-V group was 682.37 mm3, while that in the
mock, shScr-V, shSox2-V, HM-3, HM-3 + shScr-V and
docetaxel groups was 1516.32 mm3, 1194.84 mm3,
1043.85 mm3, 1129.68 mm3, 906.14 mm3 and 822.78
mm3 respectively at the end of the treatment (Fig. 3c).
The difference of tumor volume between the HM-3 +
shScr-V and HM-3 + shSox2-V group was statistically
significant (P < 0.05) implicating that the shSox2 carried
by shSox2-V contributing to the inhibition of tumor
growth. The mean weight of tumors of the HM-3 +
shSox2-V group was 0.586 g, while that in the mock,
shScr-V, shSox2-V, HM-3, HM-3 + shScr-V and
docetaxel groups was 1.420 g, 1.075 g, 0.899 g, 1.037 g,
0.783 g and 0.737 g respectively (Fig. 3d). Both shScr-V
and shSox2-V could enhance the antitumor effect of
HM-3 as compared to the mock group (P < 0.05 and P <
0.01, respectively). The best antitumor effect was
achieved in the HM-3 + shSox2-V group. Due to the
variance of tumor weight in mice, the difference of
tumor weight between the HM-3 + shScr-V and HM-3 +
shSox2-V group was not statistically significant.
The expression of Sox2 and microvessel formation in the
A549 xenografts of different treatment groups
The expression of Sox2 in the tumor tissues was exam-
ined by WB and IHC. In contrast to the groups treated
with NS, HM-3 and shScr-V, Sox2 expression was much
lower in the HM-3 + shScr-V, HM-3 + shSox2-V and
docetaxel groups (Fig. 4a, P < 0.05). When co-
administered with HM-3, shSox2-V could more effect-
ively inhibit the expression of Sox2 compared to shScr-V
(P < 0.01). The results indicated that the successful
transfection of Sox2 shRNA by VNP20009 in vivo. Doce-
taxel is a microtubule inhibitor that inhibits the disasso-
ciation of microtubule during cell division. The down
regulation of Sox2 in the docetaxel group might result
from the cell cycle arrest and cell death induced by
Fig. 1 The migration and proliferation potential of A549 cells was inhibited as Sox2 was down regulated. a The expression of Sox2 at protein level in
A549 cells was analysed using western blot after transfection. shScr, A549 cells transfected with shScr. shSox2, A549 cells transfected with shSox2. The
quantification assay of WB results was shown as mean ± SD obtained from three repeated experiments. **P < 0.01 vs shScr group. b The migration
capability of A549 cells was reduced after transfected with shSox2. Original magnification × 200. The quantification data shown was mean ± SD
obtained from three fields. **P < 0.01 vs shScr group. c The colony forming capability of A549 cells was inhibited after transfected with shSox2.
Original magnification × 200. The quantification data shown was mean ± SD obtained from three fields. *P < 0.05 vs shScr group
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docetaxel rather than a direct effect. In consistent with
the WB result, the number of Sox2 positive cells was
also reduced in the HM-3 + shScr-V, HM-3 + shSox2-V
and docetaxel groups (Fig. 4b). The number of Sox2
positive cells per field for the mock, shScr-V, shSox2-V,
HM-3, HM-3 + shScr-V, HM-3 + shSox2-V and doce-
taxel groups was 39.5, 39.25, 30.75, 41.75, 22.25, 10.5
and 13.25 respectively (Fig. 5a).
CD31 has been used extensively to evaluate the de-
gree of angiogenesis in tumors. As shown in the WB
and IHC results, the amount of CD31 was much
lower in the HM-3, HM-3 + shScr-V and HM-3 +
shSox2-V groups compared to those treated with NS,
shScr-V, shSox2-V and docetaxel (Fig. 4a and c, P <
0.05). The microvessel number per field for the
mock, shScr-V, shSox2-V, HM-3, HM-3 + shScr-V,
HM-3 + shSox2-V and docetaxel groups was 10.25,
9.75, 10.75, 3.5, 3.25, 2.5 and 9.75 respectively
(Fig. 5b). The results confirmed that HM-3 could in-
hibit the microvessel formation in tumors. The dif-
ference of microvessel density between HM-3 +
shScr-V and HM-3 + shSox2-V group was not sig-
nificant suggesting that the antiangiogenesis activity
of HM-3 was not affected in both groups.
Effects of HM-3 with shSox2-V on the expression of
apoptosis-related protein in the A549 xenografts
Histological examination showed large areas of necrosis
in the HM-3 + shScr-V, HM-3 + shSox2-V and docetaxel
groups (Fig. 6a). The accumulation of salmonella and
co-expression of Sox2 shRNA enhanced the therapeutic
effect of HM-3 on the growth of tumor. It has been re-
ported that the silencing of Sox2 leading to the up regu-
lation of apoptotic marker cleaved Caspase 3 (C-caspase
3) in lung cancer [21]. Also, it has been found that
VNP20009 could migrate away from vasculature and in-
duce apoptosis in tumor tissue [22]. Together with HM-
3 inhibiting the microvessel formation in tumors, we
assumed that tumor cells were more susceptible to the
induction of cell death. The expression of apoptosis-
related protein C-caspase 3, Bax and Bcl2 was examined
with WB (Fig. 6b). Compared to the mock group, the ex-
pression of apoptosis stimulators Bax and C-caspase 3
was much higher in the HM-3 + shSox2-V and docetaxel
groups (P < 0.05). In contrast, the expression of apop-
tosis inhibitor Bcl2 was much lower in the HM-3 +
shSox2-V and docetaxel groups (P < 0.05). Those results
suggested that the apoptosis pathway was activated in
the HM-3 + shSox2-V and docetaxel groups. The
Fig. 2 VNP20009 preferably accumulated in tumors in vivo. a The representative images of LB agar plates planted with different homogenized tissue
after serial dilution or blood on days 2 after injection. The dilution factor was marked, 1/10 for ten fold dilution. b The quantitative analyses of the
bacterium count by cfu/g tissue were presented for days 2, 7 and 14 post injections. Data shown was mean ± SD obtained from three independent
experiments. *P < 0.01 vs the tumor group on days 2, ΔP < 0.01 vs the tumor group on days 7, #P < 0.01 vs the tumor group on days 14
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difference of the expression of Bax and C-caspase 3 be-
tween the HM-3 + shScr-V and HM-3 + shSox2-V group
was statistically highly significant (P < 0.01, respectively)
indicating that shSox2 contributed to the activation of
the apoptosis pathway.
Systematic toxicity in the mice treated with HM-3 +
shSox2-V
Previous study has found that VNP20009 administered
alone can be tolerated by athymic mice [23]. The sys-
tematic safety when HM-3 and shSox2-V administered
together still requires further verification. We compared
the body weight of mice in the HM-3 + shSox2-V group
to the other groups (Fig. 7a). Those mice treated with
docetaxel had the lowest mean body weight at the end
of the study. The body weight of the mice treated with
HM-3 was about the same as the mock group. Although
the mean body weight of mice in the HM-3 + shSox2-V
group was lower than the mock group, the difference
was not statistically significant. After the tumor-bearing
mice were sacrificed, their hearts, livers, spleens, kidneys
and lungs were harvested and examined by H&E stain-
ing (Fig. 7b). As shown in the result, the combined treat-
ment with HM-3 and shSox2-V had little toxicity to the
major organs compared to the mock group.
Discussion
At the early stages of tumor progression, microvessels
are formed around tumor. If angiogenesis inhibitors are
administered at this stage, the growth of tumor could be
effectively inhibited. However, the microenvironment in
the inner tumor mass changes as tumor progresses. The
Fig. 3 Inhibition of A549 tumor growth by various treatments in vivo. a Images of the tumor-bearing mice of each group. b Images of the tumors
of each group at the end of treatments. c The mean tumor volume of each group over the 18-day treatment period. d Tumor wet weights of
each group were measured after the animals were killed. Data was shown as mean ± SD obtained from each group. *P < 0.05 vs Mock group,
**P < 0.01 vs Mock group, ΔP < 0.05 vs HM-3 + shScr-V group
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actions of antitumor drugs may be affected as the ex-
pression of various factors and microRNAs are influ-
enced by the microenvironment [24, 25]. Also, the
survival of CSCs further limits the effectiveness of
chemotherapy and anti-angiogenesis therapy [26–28]. In
this study, the treatment was started after the tumor vol-
ume was greater than 300 mm3. On one hand, polypep-
tide HM-3 was administered to suppress the microvessel
Fig. 4 Expression of Sox2 and CD31 in the tumors of each treatment group. a The expression of Sox2 and CD31 were examined with WB assays.
The quantification assay of WB results was also presented. Data shown was mean ± SD obtained from three independent experiments. *P < 0.05
vs Mock group, #P < 0.01 vs HM-3 + shScr-V group. b The representative images of IHC staining for Sox2 of tumors treated in each group. c The
representative images of IHC staining for CD31 of tumors treated in each group
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Fig. 5 The quantification analysis of the IHC result. a The Sox2 positive cells per field were counted. The data shown was mean ± SD obtained
from four fields. *P < 0.05 vs Mock group, ΔP = 0.055 vs HM-3 + shScr-V group. b The microvessel number per field was counted. The data shown
was mean ± SD obtained from four fields. *P < 0.05 vs Mock group
Fig. 6 The induction of cell apoptosis in tumors. a Representative images of H&E staining of tumors of each treatment group. b The expression
of Bax, Bcl2 and cleaved Caspase 3 (C-caspase 3) were examined with WB assays. The quantification assay of WB results was also presented. The
data shown was mean ± SD obtained from three independent experiments. *P < 0.05 vs Mock group, #P < 0.01 vs HM-3 + shScr-V group
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formation in tumor which cut the supply of oxygen and
nutrients for tumor growth. On the other hand, attenu-
ated facultative anaerobe VNP20009 was administered
which can specifically accumulate in tumor because of
its natural tropism for hypoxic areas in contrast to
chemo drugs [29]. The inhibition of microvessel forma-
tion in tumor could not affect the tumor targeting po-
tential of VNP20009 as it was cleared away from the
blood quickly and accumulated in tumors shortly after
injection. To further inhibit the survival of CSCs in
tumor tissue, a shRNA construct targeting Sox2 was
transformed into VNP20009. The expression of Sox2
was down regulated in the tumor tissue of the combined
treatment group while with much smaller tumor
volume.
The engineered salmonella enhanced the antitumor ef-
fect of HM-3 on lung cancer compared to the individual
therapy group. The inhibition rate of the HM-3 +
shSox2-V group was 58.73 %, while that in the shScr-V,
shSox2-V, HM-3, HM-3 + shScr-V and docetaxel groups
was 24.3 %, 36.69 %, 26.97 %, 44.86 % and 48.1 % re-
spectively. Our results suggested that this combination
was effective in inhibiting tumor growth in vivo. Accord-
ing to our knowledge, this was the first report that atten-
uated salmonella with a shRNA construct targeting Sox2
was co-administered with a polypeptide inhibiting angio-
genesis in the treatment of lung cancer.
Sox2 is a poor prognostic indicator in stage I lung can-
cer [30]. Also, it has been reported that the expression of
Sox2 promoted drug resistance of certain tumors [31, 32].
By knocking down the expression of Sox2 with shRNA,
the growth of lung cancer cells was inhibited. In consist-
ent with previous reports, the down regulation of Sox2
was related to the expression of apoptosis related marker
C-caspase 3 [21]. However, our results suggested that
knocking down Sox2 alone was not enough to signifi-
cantly inhibit A549 tumor growth in vivo. Considering the
redundancy of signaling factors in tumor cells, other
members of the same protein family or different pathways
may compensate for the loss of Sox2 leading to the sur-
vival of tumor cells [33, 34].
Cell death mediated by apoptosis is important in the
regulation of tumor growth. It has been reported that
VNP20009 could migrate from the vascular and induce
apoptosis in tumor [22]. Our results showed that the
apoptosis induced by VNP20009 alone was not evident.
This might be due to the difference of tumor model and
treatment regimens. More tumor cell went through
apoptosis in the HM-3 + shSox2-V group implicating
that the inhibition of angiogenesis by HM-3 had syner-
gistic antitumor effects with shSox2-V. The cell apop-
tosis pathway was also activated in the group treated
with docetaxel due to its cytotoxicity. It has been re-
ported that the combination therapy of cytotoxic agents
with salmonella was effective in inhibiting the growth of
prostate cancer [17]. However, whether this combination
can be applied to lung cancer still requires further
verification.
Conclusions
Our study suggested that HM-3 together with a gene
therapy targeting Sox2 delivered by VNP20009 was an
Fig. 7 Systematic toxicity in the mice of each treatment group. a The mean body weight of tumor-bearing mice treated in each group was measured
during the study. The data shown was mean ± SD obtained from each group. b The images of H&E staining of major organs of mice treated with NS
and HM-3 + shSox2-V
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attractive treatment option for patients with lung cancer.
However, to achieve better antitumor effect, multi-
targeting therapies with cytotoxic drugs and the use of
other gene therapy delivering system may be considered
[35]. Also, the key factors of other signal pathways that
are involved in lung cancer growth can be evaluated as
potential targets [36].
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